VEC.L Share News (VEC)
VEC Share
VEC Share
VEC Share
VEC Share
VEC
VEC Share
VEC Broker
VEC Directors
VEC Financial
VEC
VEC Short
VEC
(Makes clear Circassia raised 200 mln pounds, valuing it at 581 million) * Britain's Circassia prices record-breaking European IPO * UK, France, Switzerland seen in strong position as market takes off * Several firms weighing listing shares over trade sale By Ben Hirschler
Read moreThe FTSE Small Cap index edges up by 0.1 percent in early session trading, beating falls of 0.2 percent on the blue-chip FTSE 100 index and on the FTSE 250 mid-cap index. The junior-listed FTSE AIM All Share Index retreats by 0.6 percent. Healthcare company Vectura, whose products de
Read more
Vectura Group has announced the acquisition of Activaero, a German pharmaceutical technology company focused on respiratory diseases, and a fundraising to develop Activaero's lead product. The €130m (£108m) purchase, which will be funded through a combination of existing cash and equity, is expecte
Read more
LONDON (Alliance News) - Inhaler company Vectura Group PLC Friday said its partner Sandoz has received marketing approval for its AirFluSal Forspiro inhaler for treating asthma and chronic obstructive pulmonary disease, the first approval for the product in Asia. Vectura developed the produ
Read moreLONDON (Alliance News) - Vectura Group PLC said Thursday that its performance in the period from October 1, 2013 to date had been in line with expectations. During the period Vectura's partner Sandoz saw marketing authorisation for AirFluSal Forspiro, an inhaler for asthma or Chronic Obstru
Read moreLONDON (Alliance News) - The market is dissecting the Lloyds Banking Group earnings statement early Thursday. The state-controlled bank said it swung to profit in 2013, while confirming its intentions to restart paying a dividend and to sell off more of the UK government's sha
Read moreLONDON (Alliance News) - Vectura Group PLC Wednesday said its partner has received Belgian marketing authorisation for its new inhaler for people with asthma, triggering a payment to Vectura of EUR1.5 million. In a statement, Vectura said partner Sandoz has received approval for the AirFluS
Read moreLONDON (Alliance News) - LONDON (Alliance News) - Vectura Group PLC Monday said partner Sandoz has received marketing authorisation from Norwegian authorities for its asthma inhaler AirFluSal Forspiro. It has previously been launched in Denmark, and authorised in Germany, Sweden, Hungary, R
Read moreLONDON (Alliance News) - Vectura Group PLC Tuesday said partner Sandoz has received marketing authorisation from Bulgarian authorities for its new inhaler for patients with respiratory problems. The product, known as AirFluSal Forspiro, is an inhaler for patients with asthma and chronic obs
Read moreLONDON (Alliance News) - Vectura Group PLC said Wednesday that its partner Sandoz has received marketing approval for its AirFluSal Forspiro asthma inhaler in Romania. Vectura will receive a EUR1.5 million milestone payment as a result of the marketing authorisation. The product has alread
Read moreLONDON (Alliance News) - Vectura Group PLC said Monday that its partner Sandoz has launched its AirFluSal Forspiro asthma inhaler in Denmark. AirFluSal Forspiro received EU market authorisation in Denmark December 18 2013. Sandoz is the generics division of Swiss pharmaceutical compan
Read moreLONDON (Alliance News) - Vectura Group PLC said Thursday that its partner Sandoz, part of Novartis AG, has received marketing authorisation for its AirFluSal Forspira inhaler in Hungary. The authorisation comes after AirFluSal Forspira received marketing authorisation in Germany on Monday,
Read moreDecent gains from AstraZeneca and Shire gave the pharmaceuticals sector a boost on Tuesday as both firms gave confident outlooks. At the JP Morgan Healthcare Conference in San Francisco, AstraZeneca Chief Executive Pascal Soriot said he expects the company to return to growth sooner than analysts c
Read moreVectura, the AIM-listed respiratory development company, confirmed that its partner Sandoz, has received Swedish marketing authorisation for AirFluSal Forspiro, a new inhaler for patients with asthma and chronic obstructive pulmonary disease. The firm, which focuses on the development of pharmaceut
Read moreLONDON, Jan 14 (Reuters) - Sweden has followed Denmark and Germany in approving the sale of a generic copy of GlaxoSmithKline's $8 billion-a-year inhaled lung drug Advair. Britain's Vectura said on Tuesday its partner Sandoz, the generics division of Switzerland's Novartis , had received Sw
Read more